Insmed's (INSM) Brensocatib Trial a Disappointment - Stifel
Tweet Send to a Friend
Stifel analyst Stephen Willey reiterated a Buy rating and $212.00 price target on Insmed (NASDAQ: INSM).The analyst commented, "The failure ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
